Latest Breaking News On - Mikyoung hahn - Page 1 : comparemela.com

SAN FRANCISCO - May 9, 2022 - (Newswire.com) Blue Note Therapeutics and Bixink Therapeutics, a bio-subsidiary of KPS, today announced that the companies have entered into an exclusive lic.

South koreaSouth koreanGeoffrey eichMikyoung hahnKim kingDrug administrationBixink therapeutics coNote therapeuticsBixink therapeuticsBlue noteBlue note therapeuticsBreakthrough device designationBreakthrough deviceSouth korean bio companyRelease serviceBixink enter licensing agreement